Search results
Showing 8431 to 8445 of 8908 results
This advice has been updated and replaced by NICE healthtech guidance 602.
Personal KinetiGraph for remote clinical management of Parkinson's disease (MIB258)
This advice has been updated and replaced by NICE healthtech guidance 657.
TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)
This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.
VitalPAC for assessing vital signs of patients in hospital (MIB79)
This advice has been updated and replaced by NICE medtech innovation briefing 205.
This advice has been updated and replaced by NICE medical technologies guidance 42.
Absorb Bioresorbable Vascular Scaffold system for coronary artery disease (MIB84)
NICE withdrew this medtech innovation briefing in November 2017 after the company stopped manufacturing Absorb because of low uptake. Some UK hospitals continue to use the technology in ongoing clinical studies.
Faecal microbiota transplant for recurrent or refractory Clostridioides difficile infection (MIB247)
This advice has been updated and replaced by NICE guideline NG199.
This guidance has been updated and replaced by HealthTech guidance 639.
This guidance has been updated and replaced by NICE HealthTech guidance 643.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with cystic fibrosis see our guideline on diagnosing and managing cystic fibrosis and for people with COVID-19 see our guideline on managing COVID-19.
27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
COVID-19 rapid guideline: children and young people who are immunocompromised (NG174)
27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For children and young people with COVID-19 see our guideline on managing COVID-19.